Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in the treatment of locally advanced or metastatic breast cancer that progressed on CDK4/6 inhibitor combined with endocrine therapy.

Trial Details

NCT ID

NCT05860465

Phase

PHASE2 / PHASE3

Sponsor

Shanghai Pharmaceuticals Holding Co., Ltd

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

SPH4336 Tablets
SPH4336 Tablets Placebo

Locations (sample)

Guangzhou, Guangdong, China|23.11667,113.25
Liuchow, Guangxi, China|24.32405,109.40698
Anyang, He'nan, China|36.096,114.38278
Luoyang, He'nan, China|34.67345,112.43684
Shijiazhuang, Hebei, China|38.04139,114.47861

Key Eligibility Criteria

Patients who voluntarily participate in this study, completely understand this study, and voluntarily sign the informed consent form (ICF).
ECOG (Eastern Cooperative Oncology Group) performance status score of 0 or 1.
Life expectancy ≥ 3 months.
Patients with locally advanced or metastatic breast cancer who are unable to receive radical surgeries/other local therapies.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →